Efficient Multiproduct Process Development

Shahrockh, Zahra; Price, Stacy; Voloch, Marcio
August 2011
BioPharm International;Aug2011, Vol. 24 Issue 8, p33
Trade Publication
Case Study
The article presents a case study of enzyme replacement therapies (ERTs) for efficient multiproduct process development (PD). It describes the approach to ERT product development applicable in the development of other types of pharmaceutical products. It summarizes the effect and evolution of PD platforms created for complex enzymes to suit the accelerated development. The process of attaining efficiency through PD life cycle staged planning is also mentioned.


Related Articles

  • INDUSTRY PIPELINE.  // Pharmaceutical Technology;Oct2004, Vol. 28 Issue 10, p158 

    The article presents information about various products related to pharmaceutical industry. Charles Charles Ross and Son Co. offers its line of sanitary ribbon blenders. The blenders are manufactured in type 316 stainless steel and polished to a 150-grit finish to enable easy cleaning between...

  • Understanding Physicochemical Properties for Pharmaceutical Product Development and Manufacturing--Dissociation, Distribution/Partition, and Solubility. Zhou, Deliang; Qiu, Yihong // Journal of Validation Technology;Spring2009, Vol. 15 Issue 2, p13 

    The article discusses the physicochemical properties for pharmaceutical product development and manufacturing, as well as disassociation of weak acids and bases, distribution and partitioning between aqueous and non-aqueous liquids, and solubility. It explains the importance of knowing the...

  • Money for nothing? Risks in biopharmaceutical companies from the perspective of public financiers. Heinonen, Laura; Sandberg, Birgitta // Journal of Commercial Biotechnology;Oct2008, Vol. 14 Issue 4, p287 

    The risks faced by biopharmaceutical companies during the process of drug development are multifaceted and complicated. Furthermore, resource intensiveness and the long time perspective force them to rely on external finance. This study describes the risks in the industry along the...

  • Reinventing Invention. Van Arnum, Patricia // Pharmaceutical Technology;Dec2011, Vol. 35 Issue 12, p10 

    The article offers the author's insights on the development and reinventions of pharmaceutical product models as underlying measure of pharmaceutical industry's success in 2012.

  • Economic and Developmental Considerations for Pharmacogenomic Technology. Vernon, John A.; Johnson, Scott J.; Hughen, W Keener; Trujillo, Antonio // PharmacoEconomics;2006, Vol. 24 Issue 4, p335 

    The pharmaceutical industryʼs core business is the innovation, development and marketing of new drugs. Pharmacogenetic (PG) testing and technology has the potential to increase a drug’s value in many ways. A critical issue for the industry is whether products in development...

  • Strategic alliances as a mechanism for wealth creation in the biopharmaceutical industry: An empirical analysis of the Spanish case. Gutiérrez de Mesa Vázquez, Emma; Jiménez Martín, Juan Angel; Mascareñas, Juan // Journal of Commercial Biotechnology;Apr2006, Vol. 12 Issue 3, p229 

    The paper studies strategic alliances signed between traditional pharmaceutical companies (TPCs) and new biotechnology firms (NBFs) in Spain, on the initial basis that a firm's rate of new product development is a positive function of the number of strategic alliances that it has entered into....

  • First-in-Class Ain't What It Used to Be.  // Technology Review;Jul2005, Vol. 108 Issue 7, p29 

    This article deals with the decline in the amount of time in which a new product in the pharmaceutical sector has a market all to itself since the 1960s. By the late 1990s, it was not uncommon for a first-in-class drug, the first drug to use a particular molecular mechanism to treat a condition,...

  • Building Automation Systems in a PAT Framework. Whitney, Jonathan T.; Granger, Mark A. // BioPharm International;Sep2005, Vol. 18 Issue 9, p70 

    Reports on the role of building automation technology system in maintaining and validating quality manufacturing environments in the U.S. Provision of closed-loop feedback control and analysis of the process of manufacturing a quality environment with optimum temperature; Details on the...

  • Predevelopment: The Innovation Advantage -- A Natura Case Study. Clepf, Sabrina; Takahashi, Vania Passarini // Global Cosmetic Industry;Nov2012, Vol. 180 Issue 9, p22 

    The article presents a case study which focuses on the predevelopment phase of innovation, adopted by cosmetics manufacturer Natura Inc., and how its affects the outcome of the products development process. It is said that the predevelopment or early development phase allows to optimize the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics